Q: Who should NOT take Calcii dobesilas monohydricus?

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Q: Can Calcii dobesilas monohydricus be used during pregnancy?

Pregnancy Data on the use of calcium dobesilate in pregnant women are limited. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. As a precautionary measure, it is preferable to avoid the use of calcium dobesilate during pregnancy. Breast-feeding Calcium dobesilate is excreted into breast milk in negligible amounts (0.4 µg/ml following a dose of 3 × 500 mg). Doxium 500 is not intended for administration during breast-feeding. As a precautiona

Q: What precautions should be taken with Calcii dobesilas monohydricus?

In cases of severe renal insufficiency requiring dialysis, the dose may be reduced. In very rare cases, administration of calcium dobesilate may cause agranulocytosis (see section 4.8). In such cases, symptoms may include high fever, oral cavity infection (tonsillitis), sore throat, anogenital inflammation, and other signs commonly associated with infection. If any of these symptoms occur, treatment must be discontinued. A complete blood count and white blood cell differential must then be perfo

Q: Who manufactures Calcii dobesilas monohydricus?

Przedsiębiorstwo Produkcji Farmaceutycznej HASCO-LEK S.A. (Polska)

Question 1

What is Calcii dobesilas monohydricus used for?

Accepted Answer

Microangiopathy, particularly diabetic retinopathy.
Clinical manifestations of chronic venous insufficiency of the lower limbs (pain, cramps, paraesthesia, oedema, venostasis, dermatosis). Post-thrombotic syndrome, disorders of microcirculation of venous origin.
Haemorrhoids.
This medicinal product is intended for adult patients.

Question 2

How does Calcii dobesilas monohydricus work?

Accepted Answer

Pharmacotherapeutic group: venoactive agent, antivaricose agent
ATC code: C05BX01
Calcium dobesilate acts on the capillary wall by restoring its impaired physiological functions—increased permeability and reduced resistance.

Question 3

What is the active ingredient in Calcii dobesilas monohydricus?

Accepted Answer

Calcii dobesilas monohydricus (Calcii dobesilas monohydricum)

Question 4

What pharmaceutical form is Calcii dobesilas monohydricus available in?

Accepted Answer

Calcii dobesilas monohydricus: Tabletki powlekane 250 mg (doustna)

Question 5

Is Calcii dobesilas monohydricus OTC or prescription only?

Accepted Answer

Calcii dobesilas monohydricus is available over-the-counter (OTC) — no prescription required.

Question 6

What are the side effects of Calcii dobesilas monohydricus?

Accepted Answer

Adverse reactions are listed below by MedDRA system organ class and frequency convention:
Very common (≥1/10)
Common (≥1/100 to <1/10)
Uncommon (≥1/1,000 to <1/100)
Rare (≥1/10,000 to <1/1,000)
Very rare (<1/10,000)
Not known (cannot be estimated from the available data)
Blood and lymphatic system disorders
Very rare: agranulocytosis (see section 4.4)
Not known: neutropenia, leukopenia
Immune system disorders
Uncommon: hypersensitivity (rash, allergic dermatitis, pruritus, urticaria, facial oede

Question 7

Who should NOT take Calcii dobesilas monohydricus?

Accepted Answer

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Question 8

Can Calcii dobesilas monohydricus be used during pregnancy?

Accepted Answer

Pregnancy
Data on the use of calcium dobesilate in pregnant women are limited.
Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. As a precautionary measure, it is preferable to avoid the use of calcium dobesilate during pregnancy.
Breast-feeding
Calcium dobesilate is excreted into breast milk in negligible amounts (0.4 µg/ml following a dose of 3 × 500 mg). Doxium 500 is not intended for administration during breast-feeding. As a precautiona

Question 9

What precautions should be taken with Calcii dobesilas monohydricus?

Accepted Answer

In cases of severe renal insufficiency requiring dialysis, the dose may be reduced.
In very rare cases, administration of calcium dobesilate may cause agranulocytosis (see section 4.8). In such cases, symptoms may include high fever, oral cavity infection (tonsillitis), sore throat, anogenital inflammation, and other signs commonly associated with infection. If any of these symptoms occur, treatment must be discontinued. A complete blood count and white blood cell differential must then be perfo

Question 10

Who manufactures Calcii dobesilas monohydricus?

Accepted Answer

Przedsiębiorstwo Produkcji Farmaceutycznej HASCO-LEK S.A. (Polska)

Question 11

What ATC class does Calcii dobesilas monohydricus belong to?

Accepted Answer

Calcii dobesilas monohydricus: ATC C05BX01. ATC is the WHO Anatomical Therapeutic Chemical classification — it groups drugs by organ system and pharmacological mechanism.

Calcii dobesilas monohydricus

User Reviews